{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:10:36Z","timestamp":1792195836133,"version":"4.4.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Baclofen, a centrally acting muscle relaxant, is widely utilized for the management of muscle spasms and alcohol use disorders associated with conditions. However, its neurological safety and tolerability in a large population remain limited. This study aimed to assess the neurological safety and potential risks of baclofen in the real world.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data covering the period from the first quarter of 2004 to the third quarter of 2024 were collected from the Food and Drug Administration Adverse Event Reporting System (FAERS). Four disproportionality analysis methods were employed: the Reporting Odds Ratio, the Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and the Multi-item Gamma Poisson Shrinkage (MGPS). These methods were used to detect and evaluate adverse events Adverse drug events associated with baclofen. Additionally, the time to onset analysis was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 432 neurological-related preferred terms (PTs) were identified. The number of PT that were positive for all four algorithms was 40, and the top 5 PT were Hypotonia, Encephalopathy, Coma, Unresponsive to stimuli, and Cerebrospinal fluid leakage. The top 5 PTs for ROR values are Intracranial hypotension [ROR 66.24 (55.45\u201379.13)], Cerebrospinal fluid leakage [ROR 51.34 (45.84\u201357.51)], Autonomic dysreflexia [ROR 47.4 (32.27\u201369.63)], Basal ganglion degeneration [ROR 33.03 (18.54\u201358.84)], Sciatic nerve palsy [ROR 21.6 (11.14\u201341.87)]. The median onset time for baclofen -related ADEs was 27\u00a0days. Most cases (n = 241, 55.5%) occurred within the first month of baclofen administration. In an analysis of severe vs. non-severe ADEs, the study found that the incidence of severe cases was higher than that of non-severe cases, with no gender-related differences observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study identified clinically significant PTs using four different algorithms and performed gender subgroup analysis. The TTO analysis indicated that the onset of most ADEs occurred within 27\u00a0days. Furthermore, the frequency of severe ADEs was higher than that of non-severe ones. Clinicians should closely monitor for neurological adverse effects caused by baclofen, particularly severe ADEs, and consider individualized dosing strategies. Further research based on real-world data is needed to validate these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1569602","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:38:15Z","timestamp":1747201095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Yunhan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesheng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"CD012557","DOI":"10.1002\/14651858.CD012557.pub3","article-title":"Baclofen for alcohol use disorder","volume":"2023","author":"Agabio","year":"2023","journal-title":"Cochrane Db. Syst. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"08968608241311717","DOI":"10.1177\/08968608241311717","article-title":"Baclofinding solutions: baclofen-induced encephalopathy in a peritoneal dialysis patient","author":"AlShaqaq","year":"2025","journal-title":"Perit. Dial. Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40264-016-0489-7","article-title":"Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: an example with baclofen and alcohol dependence in France","volume":"40","author":"Auffret","year":"2017","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidem. Dr. S."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","article-title":"Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial","volume":"26","author":"Beraha","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ana.25498","article-title":"The effect of intrathecal baclofen in dyskinetic cerebral palsy: the IDYS trial","volume":"86","author":"Bonouvri\u00e9","year":"2019","journal-title":"Ann. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejpn.2022.02.002","article-title":"Surgical complications of intrathecal baclofen in children: a single centre, 20-year retrospective cohort study","volume":"37","author":"Bonouvri\u00e9","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/0883073813479668","article-title":"An unusual cause of flaccid paralysis and coma: baclofen overdose","volume":"29","author":"Caron","year":"2014","journal-title":"J. Child. Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2024.3.FOCUS2452","article-title":"History and evolution of surgical treatment for spasticity: a journey from neurotomy to selective dorsal rhizotomy","volume":"56","author":"Cespedes","year":"2024","journal-title":"Neurosurg. Focus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/pds.4635","article-title":"Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France","volume":"27","author":"Chaignot","year":"2018","journal-title":"Pharmacoepidem. Dr. S."},{"key":"B11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.kint.2020.04.047","article-title":"Baclofen has a risk of encephalopathy in older adults receiving dialysis","volume":"98","author":"Chauvin","year":"2020","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1495137","DOI":"10.3389\/fimmu.2024.1495137","article-title":"Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/STROKEAHA.118.022255","article-title":"Effect of intrathecal baclofen on pain and quality of life in poststroke spasticity","volume":"49","author":"Creamer","year":"","journal-title":"Stroke"},{"key":"B14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/jnnp-2017-317021","article-title":"Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS)","volume":"89","author":"Creamer","year":"","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/neu.2020.7591","article-title":"Role of baclofen in modulating spasticity and neuroprotection in spinal cord injury","volume":"39","author":"De Sousa","year":"2022","journal-title":"J. Neurotrauma"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1511115","DOI":"10.3389\/fphar.2025.1511115","article-title":"Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database","volume":"16","author":"Ding","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3389\/fneur.2020.00404","article-title":"Coma with absent brainstem reflexes and a burst suppression on EEG secondary to baclofen toxicity","volume":"11","author":"Farhat","year":"2020","journal-title":"Front. Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1183\/09031936.95.08020230","article-title":"The effects of the GABA agonist, baclofen, on sleep and breathing","volume":"8","author":"Finnimore","year":"1995","journal-title":"Eur. Respir. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40266-022-00946-x","article-title":"Pharmacotherapy for spine-related pain in older adults","volume":"39","author":"Fu","year":"2022","journal-title":"Drug. Aging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/s41386-021-01055-w","article-title":"Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial","volume":"46","author":"Garbutt","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.kint.2021.07.014","article-title":"Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning","volume":"100","author":"Ghannoum","year":"2021","journal-title":"Kidney Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41408-024-01023-9","article-title":"Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study","volume":"14","author":"Gong","year":"2024","journal-title":"Blood Cancer J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1417951","DOI":"10.3389\/fphar.2024.1417951","article-title":"Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups","volume":"15","author":"Guan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.apmr.2014.04.030","article-title":"Clinical relevance of pharmacological and physiological data in intrathecal baclofen therapy","volume":"95","author":"Heetla","year":"2014","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"B26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajp.2015.06.015","article-title":"High doses of Baclofen as suicide attempt in patients with alcohol use disorders - a serious concern","volume":"17","author":"Holla","year":"2015","journal-title":"Asian J. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2416926","article-title":"Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System","author":"Huang","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.mayocp.2022.11.004","article-title":"Baclofen and the risk of encephalopathy: a real-world, active-comparator cohort study","volume":"98","author":"Hwang","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/pan.13791","article-title":"The effectiveness of epidural blood patch in patients with cerebral palsy treated with intrathecal baclofen implantation","volume":"30","author":"Imerci","year":"","journal-title":"Pediatr. Anesth."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1097\/BPO.0000000000001472","article-title":"Evaluation of risk factors for cerebrospinal leakage in pediatric patients with cerebral palsy treated with intrathecal baclofen","volume":"40","author":"Imerci","year":"","journal-title":"J. Pediatr. Orthop."},{"key":"B31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1302\/1863-2548.13.190112","article-title":"Identification of complications in paediatric cerebral palsy treated with intrathecal baclofen pump: a descriptive analysis of 15 years at one institution","volume":"13","author":"Imerci","year":"2019","journal-title":"J. Child. Orthop."},{"key":"B32","doi-asserted-by":"publisher","first-page":"84.e1","DOI":"10.1016\/j.genhosppsych.2010.10.003","article-title":"A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature","volume":"33","author":"Karol","year":"2011","journal-title":"Gen. Hosp. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1017\/S0033291715002652","article-title":"Genetic overlap between impulsivity and alcohol dependence: a large-scale national twin study","volume":"46","author":"Khemiri","year":"2016","journal-title":"Psychol. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1545968308317700","article-title":"Limitations of intrathecal baclofen for spastic hemiparesis following stroke","volume":"23","author":"Kofler","year":"2009","journal-title":"Neurorehabil Neural Repair"},{"key":"B37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000112427","article-title":"Intracranial hypotension from intrathecal baclofen pump insertion. A case report and review of the literature","volume":"86","author":"Lad","year":"2008","journal-title":"Stereotact. Funct. Neurosurg."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1480994","DOI":"10.3389\/fphar.2024.1480994","article-title":"Drug-induced hearing disorders: a disproportionality analysis of the FAERS database","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1358592","DOI":"10.3389\/fphar.2024.1358592","article-title":"Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"114520","DOI":"10.1016\/j.intimp.2025.114520","article-title":"Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: a case-control study based on the FDA adverse event reporting system","volume":"153","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11916-023-01130-5","article-title":"Complex regional pain syndrome: evidence-based advances in concepts and treatments","volume":"27","author":"Limerick","year":"2023","journal-title":"Curr. Pain Headache Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.12659\/AJCR.893222","article-title":"Encephalopathy and hypotonia due to baclofen toxicity in a patient with end-stage renal disease","volume":"16","author":"Marquez","year":"2015","journal-title":"Am. J. Case Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"203936","DOI":"10.1155\/2015\/203936","article-title":"Baclofen-induced encephalopathy in end stage renal disease","volume":"2015","author":"Meillier","year":"2015","journal-title":"Case Rep. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/2042098617693571","article-title":"Baclofen overdose mimicking anoxic encephalopathy: a case report and review of the literature","volume":"8","author":"Miller","year":"2017","journal-title":"Ther. Adv. Drug Saf."},{"key":"B46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/anae.14143","article-title":"Adverse drug reactions","volume":"73","author":"Patton","year":"2018","journal-title":"Anaesthesia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis","volume":"28","author":"Pierce","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"20503121211022197","DOI":"10.1177\/20503121211022197","article-title":"Baclofen therapeutics, toxicity, and withdrawal: a narrative review","volume":"9","author":"Romito","year":"2021","journal-title":"SAGE Open Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5414\/CP203243","article-title":"Baclofen-induced neurotoxicity in patients with compromised renal function: review","volume":"56","author":"Salim","year":"2018","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40290-024-00549-4","article-title":"Disproportionality analysis and causal inference in drug safety","volume":"39","author":"Scosyrev","year":"2025","journal-title":"Pharm. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40263-024-01072-5","article-title":"Pharmacological and non-pharmacological approaches for the management of neuropathic pain in multiple sclerosis","volume":"38","author":"Shkodina","year":"2024","journal-title":"Cns Drugs"},{"key":"B52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/jimd.12638","article-title":"Deep brain stimulation and intrathecal\/intraventricular baclofen for glutaric aciduria type 1: a scoping review, individual patient data analysis, and clinical trials review","volume":"46","author":"Shlobin","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1498215","DOI":"10.3389\/fphar.2024.1498215","article-title":"Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database","volume":"15","author":"Shu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14740338.2024.2424438","article-title":"Real-world safety evaluation of atorvastatin: insights from the US FDA adverse event reporting system (FAERS)","volume":"24","author":"Wan","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/j.wneu.2022.12.039","article-title":"Intrathecal baclofen and opioid therapy: cerebrospinal fluid leak and infection incidence, risk factors, and outcomes","volume":"171","author":"Wilson","year":"2023","journal-title":"World Neurosurg."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1275814","DOI":"10.3389\/fphar.2024.1275814","article-title":"Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database","volume":"15","author":"Xia","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar.2024.1439115","article-title":"Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"112281","DOI":"10.1016\/j.forsciint.2024.112281","article-title":"Baclofen-related deaths in Australia 2000-2022","volume":"365","author":"Zahra","year":"2024","journal-title":"Forensic Sci. Int."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1437436","DOI":"10.3389\/fphar.2024.1437436","article-title":"Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1531514","DOI":"10.3389\/fphar.2025.1531514","article-title":"Real-world safety profile of elexacaftor\/tezacaftor\/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system","volume":"16","author":"Zhu","year":"2025","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1569602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:38:15Z","timestamp":1747201095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1569602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":57,"alternative-id":["10.3389\/fphar.2025.1569602"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1569602","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1569602"}}